Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | Liou J.-M.; Chen C.-C.; YU-JEN FANG ; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 9 | |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | Liou J.-M.; CHIEH-CHANG CHEN ; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 10 | |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; MING-SHIANG WU ; Taiwan Gastrointestinal Disease; Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 10 | |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | JYH-MING LIOU ; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 9 | |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; WEN-FENG HSU ; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 9 | |
2018 | 14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial | Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; CHIA-TUNG SHUN ; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium | Journal of Antimicrobial Chemotherapy | 9 | 10 | |
2010 | 18 Years Surgical Experience With Mediastinal Mature Teratoma | Chang C.-C.; Chang Y.-L.; JANG-MING LEE ; Chen J.-S.; Hsu H.-H.; Huang P.-M.; Lee Y.-C. | Journal of the Formosan Medical Association | 9 | 8 | |
2010 | 18 Years Surgical Experience With Mediastinal Mature Teratoma | Chang C.-C.; Chang Y.-L.; Lee J.-M.; Chen J.-S.; Hsu H.-H.; PEI-MING HUANG ; Lee Y.-C. | Journal of the Formosan Medical Association | 9 | 8 | |
2010 | 18 Years Surgical Experience With Mediastinal Mature Teratoma | Chang C.-C.; YIH-LEONG CHANG ; Lee J.-M.; Chen J.-S.; Hsu H.-H.; Huang P.-M.; Lee Y.-C. | Journal of the Formosan Medical Association | 9 | 8 | |
2010 | 18 Years Surgical Experience With Mediastinal Mature Teratoma | Chang C.-C.; Chang Y.-L.; Lee J.-M.; Chen J.-S.; HSAO-HSUN HSU ; Huang P.-M.; Lee Y.-C. | Journal of the Formosan Medical Association | 9 | 8 | |
2010 | 18 Years Surgical Experience With Mediastinal Mature Teratoma | Chang C.-C.; Chang Y.-L.; Lee J.-M.; JIN-SHING CHEN ; Hsu H.-H.; Huang P.-M.; Lee Y.-C. | Journal of the Formosan Medical Association | 9 | 8 | |
2008 | 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? | Yen R.-F.; Chen K.-C.; Lee J.-M.; YEUN-CHUNG CHANG ; Wang J.; Cheng M.-F.; Wu Y.-W.; Lee Y.-C. | European Journal of Nuclear Medicine and Molecular Imaging | 66 | 62 | |
2008 | 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? | Yen R.-F.; Chen K.-C.; Lee J.-M.; Chang Y.-C.; Wang J.; Cheng M.-F.; YEN-WEN WU ; Lee Y.-C. | European Journal of Nuclear Medicine and Molecular Imaging | 66 | 62 | |
2008 | 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? | RUOH-FANG YEN ; Chen K.-C.; Lee J.-M.; Chang Y.-C.; Wang J.; Cheng M.-F.; Wu Y.-W.; Lee Y.-C. | European Journal of Nuclear Medicine and Molecular Imaging | 66 | 62 | |
2008 | 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? | Yen R.-F.; Chen K.-C.; Lee J.-M.; Chang Y.-C.; Wang J.; MEI-FANG CHENG ; Wu Y.-W.; Lee Y.-C. | European Journal of Nuclear Medicine and Molecular Imaging | 66 | 62 | |
2008 | 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? | Yen R.-F.; Chen K.-C.; JANG-MING LEE ; Chang Y.-C.; Wang J.; Cheng M.-F.; Wu Y.-W.; Lee Y.-C. | European Journal of Nuclear Medicine and Molecular Imaging | 66 | 62 | |
2002 | Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer | Yuan A.; CHONG-JEN YU ; Luh K.-T.; Kuo S.-H.; Lee Y.-C.; Yang P.-C. | Journal of Clinical Oncology | 106 | 94 | |
2002 | Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer | ANG YUAN ; Yu C.-J.; Luh K.-T.; Kuo S.-H.; Lee Y.-C.; Yang P.-C. | Journal of Clinical Oncology | 106 | 94 | |
2002 | Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer | Yuan A.; Yu C.-J.; Luh K.-T.; Kuo S.-H.; Lee Y.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 106 | 94 | |
2002 | Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer | Yuan A.; Yu C.-J.; KWEN-TAY LUH ; Kuo S.-H.; Lee Y.-C.; Yang P.-C. | Journal of Clinical Oncology | 106 | 94 | |